|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||245.74 - 246.69|
|52-week range||245.74 - 246.69|
|Beta (5Y monthly)||0.64|
|PE ratio (TTM)||0.24|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
The Yahoo Finance Live team breaks down Tuesday's biggest stories, including Home Depot earnings report, the FTC suing to block Amgen's deal to buy Horizon Therapeutics, and Comcast's talks to sell its Hulu stake to Disney.
The Yahoo Finance Live team discusses stocks to watch at the closing bell, including Lowe's, Horizon Therapeutics, AMD, and Nvidia.
Yahoo Finance healthcare reporter Anjalee Khemlani joins the Live Show to discuss details surrounding the FTC suing biopharmaceutical giant Amgen Inc and its plan to block Amgen's $27.8 billion deal to acquire Horizon Therapeutics.
The regulator said its decision "sends a clear signal to the market" about consolidation in the pharmaceutical market, though analysts expect the deal will still go through despite delays.
Yahoo Finance Live discusses the sharp decline of Horizon Therapeutics shares after a report surfaced that the FTC is planning to sue to block Amgen's $28 billion purchase of the drugmaker.
Novartis CEO pushes back against government attempts to direct pharma R&D
Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.
Yahoo Finance Live co-host Seana Smith discusses stocks moving in after-hours trading.
Amgen will acquire Horizon Therapeutics for more than $26 billion as the company dives deeper into rare disease treatment.
Yahoo Finance's Anjalee Khemlani explains news of a major biotech merger as Amgen is set to acquire Horizon Therapeutics.
Notable business headlines include Amgen’s $26.4 billion acquisition of Horizon Therapeutics, Shein considering becoming an online marketplace, and expectations that the U.S. Department of Energy will announce a nuclear fusion breakthrough.
Amgen Inc. ( NASDAQ:AMGN ) is about to trade ex-dividend in the next 3 days. Typically, the ex-dividend date is one...
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
In the latest trading session, Amgen (AMGN) closed at $249.75, marking a -0.78% move from the previous day.
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo Finance’s Ines Ferre joins the Live show to break down how stocks are moving in early trading.
Amgen (AMGN) closed at $245.95 in the latest trading session, marking a +0.07% move from the prior day.
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.
These two dividend-paying pharmaceutical titans ought to keep crushing the broader markets for the foreseeable future.
Two excellent examples right now are Amgen (NASDAQ: AMGN) and Apple (NASDAQ: AAPL). Both businesses generate plenty of cash flow, have been raising their dividend payments in recent years, and investors shouldn't expect those trends to end anytime soon. Drugmaker Amgen currently pays a dividend yield of 3.1%, which is easily more than the S&P 500 average of 1.7%.
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The big shareholder groups in Amgen Inc. ( NASDAQ:AMGN ) have power over the company. Institutions often own shares in...